426 related articles for article (PubMed ID: 18230055)
21. Exposure to anthracyclines during childhood causes cardiac injury.
Lipshultz SE
Semin Oncol; 2006 Jun; 33(3 Suppl 8):S8-14. PubMed ID: 16781284
[TBL] [Abstract][Full Text] [Related]
22. A murine experimental anthracycline extravasation model: pathology and study of the involvement of topoisomerase II alpha and iron in the mechanism of tissue damage.
Thougaard AV; Langer SW; Hainau B; Grauslund M; Juhl BR; Jensen PB; Sehested M
Toxicology; 2010 Feb; 269(1):67-72. PubMed ID: 20079798
[TBL] [Abstract][Full Text] [Related]
23. Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection.
Stěrba M; Popelová O; Vávrová A; Jirkovský E; Kovaříková P; Geršl V; Simůnek T
Antioxid Redox Signal; 2013 Mar; 18(8):899-929. PubMed ID: 22794198
[TBL] [Abstract][Full Text] [Related]
24. Dexrazoxane is a potent and specific inhibitor of anthracycline induced subcutaneous lesions in mice.
Langer SW; Sehested M; Jensen PB
Ann Oncol; 2001 Mar; 12(3):405-10. PubMed ID: 11332155
[TBL] [Abstract][Full Text] [Related]
25. Evaluating the role of dexrazoxane as a cardioprotectant in cancer patients receiving anthracyclines.
Pouillart P
Cancer Treat Rev; 2004 Nov; 30(7):643-50. PubMed ID: 15531396
[TBL] [Abstract][Full Text] [Related]
26. Clinical pharmacology of dexrazoxane.
Hochster HS
Semin Oncol; 1998 Aug; 25(4 Suppl 10):37-42. PubMed ID: 9768822
[TBL] [Abstract][Full Text] [Related]
27. Successful dexrazoxane treatment of a potentially severe extravasation of concentrated doxorubicin.
Conde-Estévez D; Saumell S; Salar A; Mateu-de Antonio J
Anticancer Drugs; 2010 Sep; 21(8):790-4. PubMed ID: 20671512
[TBL] [Abstract][Full Text] [Related]
28. Preclinical animal models of cardiac protection from anthracycline-induced cardiotoxicity.
Herman EH; Ferrans VJ
Semin Oncol; 1998 Aug; 25(4 Suppl 10):15-21. PubMed ID: 9768819
[TBL] [Abstract][Full Text] [Related]
29. Prevention of chronic anthracycline cardiotoxicity in the adult Fischer 344 rat by dexrazoxane and effects on iron metabolism.
Cusack BJ; Gambliel H; Musser B; Hadjokas N; Shadle SE; Charlier H; Olson RD
Cancer Chemother Pharmacol; 2006 Oct; 58(4):517-26. PubMed ID: 16555089
[TBL] [Abstract][Full Text] [Related]
30. Ameliorating anthracycline cardiotoxicity in children with cancer: clinical trials with dexrazoxane.
Wexler LH
Semin Oncol; 1998 Aug; 25(4 Suppl 10):86-92. PubMed ID: 9768829
[TBL] [Abstract][Full Text] [Related]
31. Dexrazoxane-a promising antidote in the treatment of accidental extravasation of anthracyclines.
Jensen JN; Lock-Andersen J; Langer SW; Mejer J
Scand J Plast Reconstr Surg Hand Surg; 2003; 37(3):174-5. PubMed ID: 12841619
[TBL] [Abstract][Full Text] [Related]
32. Dexrazoxane treatment of doxorubicin extravasation injury in four dogs.
Venable RO; Saba CF; Endicott MM; Northrup NC
J Am Vet Med Assoc; 2012 Feb; 240(3):304-7. PubMed ID: 22256846
[TBL] [Abstract][Full Text] [Related]
33. Dexrazoxane treatment for intrathoracic anthracycline extravasation.
Schulmeister L
Onkologie; 2008 Nov; 31(11):634. PubMed ID: 19145099
[No Abstract] [Full Text] [Related]
34. European trials with dexrazoxane in amelioration of doxorubicin and epirubicin-induced cardiotoxicity.
Lopez M; Vici P
Semin Oncol; 1998 Aug; 25(4 Suppl 10):55-60. PubMed ID: 9768825
[TBL] [Abstract][Full Text] [Related]
35. Re: Totect: a new agent for treating anthracycline extravasation.
Ward MS
Clin J Oncol Nurs; 2007 Oct; 11(5):613; author reply 613. PubMed ID: 17962168
[No Abstract] [Full Text] [Related]
36. Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin.
Hofland KF; Thougaard AV; Sehested M; Jensen PB
Clin Cancer Res; 2005 May; 11(10):3915-24. PubMed ID: 15897593
[TBL] [Abstract][Full Text] [Related]
37. Strategies for reduction of anthracycline cardiac toxicity.
Speyer J; Wasserheit C
Semin Oncol; 1998 Oct; 25(5):525-37. PubMed ID: 9783592
[TBL] [Abstract][Full Text] [Related]
38. Management of anthracycline extravasation injuries.
Reeves D
Ann Pharmacother; 2007 Jul; 41(7):1238-42. PubMed ID: 17550954
[TBL] [Abstract][Full Text] [Related]
39. The cardioprotective effect of the iron chelator dexrazoxane (ICRF-187) on anthracycline-mediated cardiotoxicity.
Kwok JC; Richardson DR
Redox Rep; 2000; 5(6):317-24. PubMed ID: 11140743
[TBL] [Abstract][Full Text] [Related]
40. [Subacute cardiotoxicity caused by anthracycline therapy in children: can dexrazoxane prevent this effect?].
Erlaky H; Tóth K; Szabolcs J; Horváth E; Kemény V; Müller J; Csóka M; Jókúti L; Erdélyi D; Kovács G
Magy Onkol; 2006; 50(1):25-32. PubMed ID: 16617380
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
